Zevra Therapeutics, Inc. ZVRA EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s EPS (basic)?
- Zevra Therapeutics, Inc. (ZVRA) reported EPS (basic) of $0.62 in Q1 2026.
- How has Zevra Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Zevra Therapeutics, Inc.'s EPS (basic) increased by 1133.3% year-over-year, from -$0.06 to $0.62.
- What is the long-term trend for Zevra Therapeutics, Inc.'s EPS (basic)?
- Over 2 years (2023 to 2025), Zevra Therapeutics, Inc.'s EPS (basic) has grown at a 2.7% compound annual growth rate (CAGR), from -$1.30 to $1.37.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.